Abstract
Introduction
The treatment for breast and prostate cancer are under intense progress.
Cancer of the prostate is the second most frequently diagnosed cancer in men
in the US and approximately 3 million women in the US are living with breast
cancer. Several new approvals have changed the landscape of options for the
treatment of late stage breast and prostate cancer. Newly approved drugs are
showing increased sale figures, and several of them are reaching for broader
indications. So, the trend of continuously increasing revenues is expected for
drugs presenting reliable clinical data to support their successful progress.
Research and analysis highlights
In the report "Prostate & Breast Cancer - New Treatments & Developmental
Progress" BioSeeker does not only describe and analyze the latest years of
progress but as well provide an insight and framework to understand the
complex field of prostate & breast cancer therapeutics. In this report, we
provide one of the most comprehensive coverage of the R&D trends to set the
future marketplace. BioSeeker presents both an overview and a detailed
description on the progress of key drugs in Phase III and II development,
together with general descriptions on drugs and targets. We have identified
approximately 200 drug candidates in clinical stage of development and more
than 125 companies are involved in the development of these drugs. Among these
drugs we clearly see substantial progress while others have failed. There will
be a more intense competition in these markets and current treatments will be
changed for the benefit of more innovative therapies.
Scope of this report
- Thorough examination of status and impact of several novel drugs in
development
- Discussion of the challenges in current and future treatment strategies
- Anticancer pipeline of most companies in the field
Key reasons to read this report
- Explore the strengths and weaknesses associated with compounds in clinical
development. Scientific rationale for most novel therapeutics in breast and
prostate cancer R&D, and the results of clinical trials to date
- Gain insight into the current challenges and commercial opportunities
associated with breast and prostate cancer therapy
- Two hundred high quality references
| 
View Cart
